Tigecycline therapy in pediatric patients with multidrug resistant bacteremia

Ozkaya-Parlakay A., Gulhan B., Kanik-Yuksek S., Guney D., Gonulal D., Demirtas G., ...Daha Fazla

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, cilt.38, sa.10, ss.471-473, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 10
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.eimc.2019.12.018
  • Dergi Adı: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, DIALNET
  • Sayfa Sayıları: ss.471-473
  • Gazi Üniversitesi Adresli: Hayır

Özet

Introduction: Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients. Methods: In this study the effectiveness and safety of tigecycline in children was assessed retrospectively. Results: A total of 36 pediatric patients, received tigecycline therapy with a median of 13 days (2-32 days). Tigecycline was used as a combination therapy in all cases. Microbiological eradication was achieved in 27 patients (75%) and clinical response was observed in 30 patients (83%). There were six cases (17%) of relapse. Conclusion: Our findings suggest that tigecycline may be an option for children with severe infections due to multidrug resistant bacteria. (C) 2020 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. All rights reserved.